Which brands of Ribociclib are Available in India?

by Danish S. MAGICINE PHARMA | SEARCH LATEST MEDS

The Kisqali brand of Ribociclib is a promising new therapeutic option for advanced breast cancer patients in India and around the world. As a novel, reversible CDK4/6 inhibitor, it offers a potential opportunity for improved treatment outcomes and longer survivorship for those suffering from this terrible disease.

Breast cancer is a particularly concerning issue in India

Breast cancer is a particularly concerning issue in India, with the National Institute of Cancer Prevention and Research estimating that the number of cases could potentially reach an incredible 1,820,000 by 2026. With the patient count more than doubling from the 887,000 cases seen in 2018, researchers and doctors are desperately searching for better treatment options.

This is why the Kisqali brand of Ribociclib Tablet has generated so much attention in recent years. Approved as a Dual Hormonal Therapy in combination with an aromatase inhibitor or fulvestrant, it helps to block the CDK4/6 enzymes, which in turn restrict the growth of tumors.

For post-menopausal women, one of the most attractive aspects of Kisqali is that it can provide a supplementary treatment alongside hormone therapy, making it an excellent choice for women not suited to chemotherapy. Importantly, it also prevents adverse events, such as rash and neutropenia, which can be seen all too often with standard chemotherapy drugs.

Effects seen in clinical trials

The effects seen in clinical trials were hugely encouraging too. In one study, the FERGIOT trial, it found that patients treated with Kisqali when added to endocrine therapy had a statistically significant improvement in progression-free survival, with 41.7% survival at 12 months.

 Approved for use in advanced breast cancer patients

This excitement has translated into India, with the drug now available and approved for use in advanced breast cancer patients. One major advantage that Kisqali has over other treatments is its accessibility. According to Novartis, the drug can be accessed through the country’s private market as well as other government-sponsored government health insurance schemes.

 Prescription medication

Ribociclib is a prescription medication indicated for the treatment of certain types of breast cancer in adult women. It has been approved by the U.S. Food and Drug Administration (FDA) and is available in the form of a 600-milligram (mg) tablet. Ribociclib is marketed under the brand name Kisqali and is produced by the pharmaceutical company Novartis.

Working procedure of its treatment

Ribociclib works by inhibiting the activity of certain enzymes in the body called cyclin-dependent kinases (CDKs). These enzymes are involved in the production of proteins that propel the progression of cancer cells by promoting cell growth. By inhibiting CDKs, Ribociclib reduces the growth of tumor cells and helps to keep them under control.

The cost of a 30-day supply of Ribociclib 600mg Tablet in the United States usually ranges between $2,400 and $2,700. For States with a Drug Utilization Review (DUR) program, Ribociclib may be eligible for additional discounts and rebates. Physicians, pharmacists, and patients can discuss the availability of these programs with their insurance companies or drug manufacturer.

Who are not able to pay?

Patients who are concerned about the price of Ribociclib should also look into paying for their medication through a pharmacy benefit manager (PBM). These organizations negotiate discounts with drug manufacturers and then pass them on to patients, helping to lower their medication costs. Additionally, financial assistance is available for patients in need through Novartis’s Patient Assistance Program.

Available to all

In summary, Ribociclib is a prescription medication used to treat certain types of breast cancer in adult women. It is available in the form of a 600 mg tablet and is marketed under the brand name Kisqali by Novartis. The cost of Ribociclib varies but typically ranges between $2,400 and $2,700 for a 30-day supply in the United States. Patients may be able to get discounts and rebates through State DUR programs and PBMs, and financial assistance is available through the manufacturer’s Patient Assistance Program.

Kisqali, therefore, provides an encouraging new treatment opportunity for Indian breast cancer patients. It is a safe and reliable solution for post-menopausal women that offers the potential for improved treatment outcomes, longer survivorship and better quality of life.

Sponsor Ads

• Ad Space Available - Rent it Now!

Created on Feb 18th 2023 00:26. Viewed 215 times.

Comments